Human cytomegalovirus gB polypeptide
The present invention relates to a polypeptide that includes at least one mutation in the fusion loop 1 region and/or in the fusion loop 2 region and/or in the furin-like cleavage site of a human cytomegalovirus gB polypeptide. In one embodiment, the polypeptide undergoes a structural conformation change in response to pH change.
1. A polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 1.
2. A polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 2.
3. A polypeptide comprising the amino acid sequence set forth in SEQ ID NO: 7.
4. The polypeptide according to any one of claims 1 - 3 , wherein the polypeptide does not include the cytoplasmic tail of HCMV gB.
5. The polypeptide according to any one of claims 1 - 3 , wherein the polypeptide does not contain an insect cell pattern of glycosylation.
6. The polypeptide according to any one of claims 1 - 3 , wherein the polypeptide has been contacted with ethylenediaminetetraacetic acid (EDTA).
7. The polypeptide according to any one of claims 1 - 3 , wherein the polypeptide undergoes a structural conformation change in response to a pH change.
8. A composition comprising the polypeptide according to any one of claims 1 - 3 , and a diluent.